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ABSTRACT
The authors present a short summary of the current state of malaria vaccine development and the per-
spectives for the availability of a malaria vaccines for travellers from non-endemic countries. There is 
currently no commercially available malaria vaccine for travellers. The efficacy of the RTS,S/AS01 vaccine 
is limited and differs dramatically from the effects of other vaccines administered in travel medicine. In 
the current recommendations, the use of repellents is deemed the most important measure to prevent 
malaria infection, and in the high-risk destinations, chemoprophylaxis is strongly advised. Many questions 
in malaria vaccinology remain unanswered. 
(Int Marit Health 2019; 70, 1: 65–67)
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INTRODUCTION
Malaria is a parasitic, vector-borne disease transmitted 
mainly through the bites of Anopheles mosquitoes. There 
are five species of the Plasmodium parasite that can infect 
humans — P. falciparum, P. vivax, P. ovale, P. malariae 
and P. knowlesi. The first one, Plasmodium falciparum, is 
known to be the most serious cause of malaria morbidity 
and mortality concentrated in sub-Saharan africa, where 
limited access to medical services and poor living conditions 
contribute to intense malaria transmission [1, 2]. 
The individual susceptibility to the disease varies, depend-
ing on the age and the natural immunity acquired as a result 
of repeated episodes of malaria infection. Young children and 
non-immune population (e.g. travellers) are at risk of the most 
severe forms of the disease. The mechanism of this progressive 
protection against malaria infection is not fully understood [2]. 
according to the World Malaria report 2018, there were 
219 million cases of malaria worldwide and 435,000 deaths 
in 2017. Ninety-two per cent of malaria infections and 93% 
deaths occurred in the World Health Organisation (WHO) 
african region. Children under the age of 5 years are the 
most affected group. The number of malaria infections de-
clined between 2010 and 2015, but no significant reduction 
was noted thereafter, and 10 african countries reported an 
increase in the incidence rate of malaria [3].
The united Nations (uN) Millennium Development Goals 
were adopted in September 2000 and signed by 191 uN 
members. among the 8 Development Goals, three of them 
aimed for combating malaria along with reducing child 
and maternal mortality. These ambitious goals were to be 
achieved by 2015 [4]. The declaration has been followed by 
the Global Technical Strategy for Malaria 2016–2030 and 
Action and Investment to defeat Malaria 2016–2030 — for 
a malaria-free world [5].
KEY INTERVENTIONS 
The success in the reduction of number of malaria cases 
has been attributed to the application of the so-called key 
interventions. In many african countries, the implemented 
malaria control programmes of proven efficacy have relied on:
 — LLINs — use of long-lasting insecticidal bed nets;
 — IrS — indoor residual spraying;
 — rDTs — rapid diagnostic tests;
 — aCTs — artemisinin combination therapies [2].
In some african settings, a fifth strategy has been in-
volved, SMC — seasonal malaria chemoprevention with the 
administration of full course of malaria treatment to young 
children at monthly intervals during malaria season [6]. 
although individual protective measures against mosquito 
bites the improvement in diagnosis and treatment of malaria 
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prove to be very efficient, the eradication of the disease 
seems to be unachievable without a vaccine [7].
MALARIA VACCINE CANDIDATES
Plasmodium parasite is a complex eukaryotic organism 
and has a complicated life cycle involving two hosts: mos-
quito and human. More than 30 Plasmodium falciparum 
vaccines are in development [8] and one has completed 
Phase III clinical testing. Plasmodium vivax is only distantly 
related to P. falciparum and has a different biology; only two 
subunit vaccines have reached clinical trials [1]. 
Currently investigated malaria vaccine candidates are 
designed as pre-erythrocytic vaccines: whole sporozoite 
and liver-stage subunit, blood-stage vaccines and transmis-
sion-blocking vaccines. 
The whole sporozoite vaccine (WSV) strategy has demon-
strated high level of protection and includes administration 
of live-attenuated sporozoites or live sporozoites accompa-
nied with antimalarial drugs. This approach aims to prevent 
the blood-stage infection. The first whole sporozoite vaccine 
contained radiation-attenuated parasites (PfSPZ Vaccine) 
and relied on intravenous administration with subsequent 
eliciting of potent immunity in humans. Cytotoxic CD8+ 
T cells response is the main immune mechanism responsi-
ble for sterile protection after WSV administration [9]. The 
first clinical trial using genetically modified Plasmodium 
(GaP) is promising; the parasite used lacks two genes re-
quired for breakthrough infection [9]. 
Liver-stage subunit vaccine focuses on identifying 
antigens on parasitized hepatocytes resulting in their de-
struction. Vaccination should generate strong CD8 + T cell 
response against infected liver cells. Phase 2b field trial 
provided 20–25% sterile protection against controlled hu-
man malaria infection [10].
Blood-stage vaccines are based on merozoite antigens 
and inducing antibodies that block erythrocyte invasion. 
Production of a broad spectrum of antibodies against mero-
zoites and infected erythrocytes induces naturally acquired 
immunity to malaria infection [9].  
Transmission-blocking vaccines are designed to impact 
the parasite’s life cycle in the mosquito and not in the 
human body to prevent its further transmission [9]. These 
approaches focus on protection of the community and im-
pact on public health than on individuals herd immunity. 
ThE RTS,S/AS01 VACCINE
The most advanced vaccine is composed of the repeat 
region of circumsporozoite protein (CSP) added to the hep-
atitis B virus surface antigen (HBsag) and aS01 adjuvant, 
leading to the induction of high level of human immunity 
(antibody titres) [7, 9]. In July 2015, the rTS,S/aS01 vaccine 
marketed by GlaxoSmithKline under the brand Mosquirix 
was the first and so far the only one to receive a positive 
regulatory assessment issued by the European Medicines 
agency [11]. The vaccine belongs to the sporozoite subunit 
vaccine (pre-erythrocytic) group. 
a phase 3 trial involved 15,460 children in 7 sub- 
-Saharan countries. all children received three doses of 
immunisation at 1-month intervals and were divided in two 
age groups: infants aged 6–12 weeks and young children 
aged 5–17 months. The fourth dose was administered after 
18–20 months. The rTS,S/aS01 trial began in 2009 and 
has recently been completed [2]. 
During over 48 months of follow-up, the efficacy of 
rTS,S/aS01 was estimated to be 36.3% in older group after 
four doses of immunisation and 28.3% after three doses. 
The observation period for infants was shorter; during over 
38 months of follow-up, the protection against clinical ma-
laria was assessed to be 25.9% after four doses and 18.3% 
after three doses [12]. Thus, the efficacy is moderate in the 
group of older children, but it is not sufficient in infants to 
encourage further studies. 
The rTS,S/aS01 was generally well tolerated in the 
trials, with typical side effects similar to other established 
childhood vaccines. among older children, an increased 
risk of febrile seizures was identified, albeit without any 
serious consequences of these episodes [2]. There were 
also 16 cases of meningitis with 8 deaths and cerebral 
malaria cases, only in the older children group. a clear link 
between meningitis or cerebral malaria and administration 
of the rTS,S/aS01 remains unconfirmed and needs to be 
evaluated in pilot study that has begun in africa [2]. 
The level of protection depends on the antibody titre 
against sporozoite surface and wanes over time [12, 13]. 
The major limitations of the rTS,S/aS01 vaccine include 
only moderate level of protection, the number of doses to 
maintain the efficacy (high antibody titres), the delivery 
system in the african countries, the cost of vaccine, the 
probable interference with the maternally acquired anti-
bodies against Plasmodium, the side effects and safety 
issues of the vaccine. 
A MALARIA VACCINE FOR TRAVELLERS?
There is currently no commercially available malaria vac-
cine for travellers. The efficacy of the rTS,S/aS01 vaccine is 
limited and differs dramatically from the effects of other vac-
cines administered in travel medicine. For example, the vac-
cine against yellow fever results in nearly-total immunity within 
1 month for 99% of people vaccinated [14]. Other candi-
dates for vaccines against malaria are not similarly ad-
vanced in development and clinical trials. 
What is the correct prevention for travellers? Currently, 
the principles of malaria prophylaxis rely on the key inter-
ventions, the same ones, as successfully implemented in 
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the endemic regions. The vaccine rTS,S/aS01 has not been 
designed for and tried in non-immune and adult population. 
In the current recommendations, the use of repellents has 
been singled out as the most important measure to prevent 
malaria infection, and in the high-risk destination, chemo-
prophylaxis is strongly advised [15]. 
The vaccine rTS,S/aS01 is only one of the key interven-
tion in malaria endemic countries to preserve health and 
life of young children. as the sole prophylactic measure, it 
would not eradicate malaria disease to the year 2030, as 
it has been planned. Furthermore, without improving the 
vaccine efficacy, the 2030 goal will be difficult to achieve 
even with intensive implementation of well-established key 
interventions. 
CONCLUSIONS
Many questions in malaria vaccinology remain unan-
swered: When will we receive the next-generation vaccine? 
Can whole sporozoite vaccines be improved or should we 
rather search for another adjuvants or components? What 
is the optimal schedule, doses, intervals and timing of boost-
er? Should we include any additional antigens or genes 
along with the ones currently used or investigated? and 
should we maybe eliminate any of them? What do we know 
about human immunity against malaria infection? Does the 
level of anti-CSP truly correspond to the efficacy of vaccine 
rTS,S/aS01? Will there be anything in the future that we 
could offer for the travellers wishing to be immunised? 
Does immunity maternally acquired confer with antibodies 
induced by vaccination? Should we expect a rebound in 
malaria morbidity as a result of key interventions failures 
(resistance of mosquitoes to repellents and insecticides, 
spreading of resistance to artemisinin in the parasite’s 
populations)? 
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